Overview
- Investigators at the 2026 SGO meeting reported that cadonilimab plus carboplatin/paclitaxel produced an objective response in 78% of 41 evaluable patients.
- The single-arm CARE study treated 45 patients and saw disease control in 97.6% of evaluable cases.
- Median progression-free survival reached 17.77 months and the 12-month overall survival rate was 88.1%, with median overall survival not yet reached.
- Responses were seen in both mismatch repair groups, including a population that was 80% pMMR, and median PFS was not reached in dMMR disease.
- Grade 3 or 4 treatment-related side effects occurred in 17.8% of patients with no grade 5 events, and investigators called for randomized trials to confirm benefit.